Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GB-5267 - IV only
GB-5267- only · 1 trial · 1 indication
Determine the MTD by assessing the incidence of dose limiting toxicities (DLTs) of GB-5267
Evaluated using the Clopper-Pearson method
| Arm | Type | Description |
|---|---|---|
| IV Only | EXPERIMENTAL | Patients receive IV only infusion of GB-5267 cells |
| Dose Expansion with Combined IV and IP Infusion | EXPERIMENTAL | A combined administration of both IV and IP infusions. |
| Name | Type | Description |
|---|---|---|
| GB-5267 - IV only | BIOLOGICAL | IV infusion |
| GB-5267 -Combined IV and IP Infusion | BIOLOGICAL | IV and IP Infusion |
Inclusion Criteria: * At least 18 years of age * Patients must have epithelial ovarian, peritoneal, or fallopian tube cancer that is confirmed by histology or cytology, with a histopathological diagnosis of serous, clear cell, endometrioid, mucinous carcinoma, or carcinosarcoma. * Must have platinu...
GB-5267 is an investigational monoclonal antibody being developed for the treatment of platinum-resistant ovarian cancer. It is also being studied for platinum-resistant peritoneal or fallopian tube cancer. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
GB-5267 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. The drug is being evaluated in a biomarker-selected patient population, suggesting it may target a specific molecular pathway relevant to platinum-resistant ovarian cancer.
GB-5267 is being developed by Generate Biomedicines, Inc., a biopharmaceutical company. The company is listed under the ticker symbol GENB. Generate Biomedicines is conducting clinical trials to evaluate the safety and efficacy of GB-5267 in patients with platinum-resistant ovarian cancer.
GB-5267 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is designed to assess the safety, tolerability, and preliminary efficacy of GB-5267 in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
GB-5267 is being studied in a single Phase 1 clinical trial with the identifier NCT07489287. The trial is titled 'GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer' and is expected to enroll 18 patients aged 18 years and older. The study is not yet recruiting participants.
Yes, GB-5267 is also known as GB-5267 - IV only, indicating that the drug is administered intravenously. The alternative name is used to specify the route of administration in clinical trial settings. Both names refer to the same investigational monoclonal antibody being developed by Generate Biomedicines.